Nasopharyngeal carcinoma
Conditions
Interventions
Experimental group:Capecitabine adjuvant chemotherapy
Control group:None
Sponsors
Anhui Provincial Cancer Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Patients with locally advanced nasopharyngeal carcinoma who received radiotherapy or 4-8 weeks after radiotherapy were positive for EBV-DNA; 2.Aged 18 to 70 years; 3.KPS>=70 points; 4.During radiotherapy, platinum weekly chemotherapy was synchronized, and the radiotherapy dose was >=66Gy (whether or not induced chemotherapy was received); 6.Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Being treated with other anti-tumor drugs; 2.Have a prior or concurrent diagnosis of other malignant tumors (except those that have been cured and have survived for more than 5 years without cancer); 3.Have received adjuvant chemotherapy in the past; 4.Pregnancy or breastfeeding; 5.Kidney disease, severe cardiovascular and cerebrovascular disease, mental illness, uncontrolled diabetes and other diseases; 6.Liver and kidney function were impaired and bone marrow function was inhibited.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Acute phase toxicity;Long term toxicity;Distant metastasis rate; | — |
Countries
China
Contacts
Public ContactGao Jing
Anhui Provincial Cancer Hospital
Outcome results
None listed